IBCSG 58-18 EXPERT

  • „This is a randomised, phase III, non-inferiority trial evaluating radiation therapy (RT) versus observation (no RT) following breast conserving surgery in patients who are planned to receive adjuvant endocrine therapy for stage I breast cancer of luminal A subtype and Risk of Recurrence (ROR) score ≤60 characterised using Prosigna (PAM50) Assay.”

    • Monitoring
      ETOP IBCSG Partners Foundation
      Coordinating Center, Bern, Switzerland
      Phone: +41 31 511 94 00
      Fax: +41 31 511 94 01
      Email: This email address is being protected from spambots. You need JavaScript enabled to view it.

       

      Trial Coordinator
      Meredith Kissel

      IBCSG Data Management Center/Frontier Science Foundation
      4033 Maple Road
      Amherst, New York 14226 USA
      Phone: +1 716 834 0900
      Fax: +1 716 833 3990
      Email:       This email address is being protected from spambots. You need JavaScript enabled to view it.

       

      Final Accrual
      1176

    ETOP IBCSG Partners Foundation
    Effingerstrasse 33
    3008 Bern, Switzerland

    Contact
    Phone: +41 31 511 94 00
    E-mail: contact@etop.ibcsg.org

    Member Login